You are here : Home » Lakeland Regional Cancer Center » Research and Clinical Trials » Pancreatic Cancer
Print Page
Pancreatic Cancer
Clinical Trial #C80701:
-
Everolimus with or without Avastin plus Octreotide for patients with neuroendocrine tumors of the pancreas that have spread.
-
Participants may have a well or moderately differentiated neuroendocrine tumor that is unresectable or metastatic, pancreatic primary, with evidence of progression within the last 12 months. Prior treatment is allowed, except for Avastin.
-
Exclusions include, but are not limited to: Uncontrolled hypertension, severe liver disease, severely impaired respiratory function, cholesterol levels of 300 or higher and metastatic disease to the brain or central nervous system.
Clinical Trial #0848:
-
The use of Gemzar, with or without an oral agent, followed by radiation and chemotherapy for cancer located in the head of the pancreas that was surgically removed.
-
Participants can be staged as a T1, T2 or T3/No-N1/M-0 and must start the protocol treatment between 21-56 days post op. Oral nutrition must be at least 1,500 calories daily.
-
Exclusions include, but are not limited to: Prior malignancy within the past 2 years, prior radiotherapy or chemotherapy, pancreatectomy alone or positive surgical margins.
Clinical Trial #Z5041:
-
Chemotherapy before and after surgery for adenocarcinoma of the head or uncinate process of the pancreas.
-
Participants CA 19-9 must be less than 1,000 and weight loss must be below 15% from their pre-disease weight.
-
Exclusions include, but are not limited to: Visceral or peritoneal metastases, occlusion of the superior mesenteric vein, active infection that is requiring IV antibiotic or evidence of tumor extension to the celiac axis, hepatic artery or superior mesenteric artery.
